Is CBD a dietary ingredient or a drug? US FDA ‘appears to have changed its mind’

Frustration with the lack of a clear regulatory pathway to market for CBD products in the US is demonstrated by recent industry responses to the denial of a new dietary ingredient (NDI) approval by the US Food and Drug Administration (FDA) for full spectrum hemp extracts.

The nub of the problem appears to be disagreement between the FDA and the industry over whether CBD should be classed as a drug or a dietary supplement.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Pablo Sharrock
+34 722 642 678
Email Pablo